Exelixis Inc (EXEL)

19.80
0.50 2.59
NASDAQ : Health Care
Prev Close 19.30
Open 19.39
Day Low/High 19.15 / 20.16
52 Wk Low/High 3.55 / 8.74
Volume 3.93M
Avg Volume 3.90M
Exchange NASDAQ
Shares Outstanding 292.51M
Market Cap 5.76B
EPS -0.30
P/E Ratio 492.00
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ANH, DVN, EXEL, FMC, FSI, GLT, MEOH, MJCO, MOH, NVO, RPXC, TECH, WU, WWE Downgrades: CIGI, IPHI, QUOT Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Biotech Movers: Luminex, Exelixis, AMAG Pharmaceuticals

Luminex, Exelixis, AMAG Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

Exelixis Announces First Quarter 2017 Financial Results And Provides Corporate Update

Exelixis Announces First Quarter 2017 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the first quarter of 2017 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development...

Exelixis To Present At The Deutsche Bank 42nd Annual Health Care Conference On May 3

Exelixis To Present At The Deutsche Bank 42nd Annual Health Care Conference On May 3

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.

Exelixis To Release First Quarter 2017 Financial Results On Monday, May 1, 2017

Exelixis To Release First Quarter 2017 Financial Results On Monday, May 1, 2017

Exelixis, Inc. (NASDAQ: EXEL) announced today that its first quarter 2017 financial results will be released on Monday, May 1, 2017 after the markets close.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 26,750 shares of Exelixis common stock and stock options to purchase an aggregate of 53,500...

Exelixis Further Reduces Indebtedness By Repaying Silicon Valley Bank Term Loan

Exelixis Further Reduces Indebtedness By Repaying Silicon Valley Bank Term Loan

Exelixis, Inc. (Nasdaq:EXEL) today announced that it has repaid all amounts outstanding under its term loan with Silicon Valley Bank initiated in 2010 and which was due for repayment on May 31, 2017.

Exelixis To Present At The Needham & Company Healthcare Conference On April 4

Exelixis To Present At The Needham & Company Healthcare Conference On April 4

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis' Cabozantinib Granted Orphan Drug Designation For The Treatment Of Hepatocellular Carcinoma

Exelixis' Cabozantinib Granted Orphan Drug Designation For The Treatment Of Hepatocellular Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 11,000 shares of Exelixis common stock and stock options to purchase an aggregate of 22,000...

Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering upon its key corporate objectives, as well as commercial and...

Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors

Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability of cabozantinib, Exelixis' tyrosine kinase inhibitor (TKI), in...

Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma

Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical development collaboration to evaluate CABOMETYXâ„¢ (cabozantinib), Exelixis' small...

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Jim Cramer isn't worried about a correction: He says this recent rally isn't just about Trump's agenda. It's about profits and earnings.

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Jim Cramer is bullish on Box, Nucor, and American Airlines; but bearish on AK Steel Holdings and Rite Aid.

Hopes for Tax Reform, Less Regulation Lift Indices

Hopes for Tax Reform, Less Regulation Lift Indices

Technical indicators indicate the markets are not extended and have consolidated nicely.

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017 after the markets close.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 61,750 shares of Exelixis common stock and stock options to purchase an aggregate of 123,500...

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis, Inc. (NASDAQ:EXEL) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib,...

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.